8-K: Jaguar Health Restructures Royalty Debt with Issuance of New Series M Preferred Stock

Jaguar Health, Inc. has reduced its outstanding royalty interest obligations by $6.5 million through the issuance of Series M Perpetual Preferred Stock to Iliad Research and Trading, L.P. and Streeterville Capital, LLC.

Summary

• Jaguar Health, Inc. entered into privately negotiated exchange agreements with Iliad Research and Trading, L.P. and Streeterville Capital, LLC on June 27, 2025.
• The company issued 170 shares of Series M Perpetual Preferred Stock to Iliad in exchange for a $4,250,000 reduction in the outstanding balance of the October 2020 Royalty Interest.
• The company issued 90 shares of Series M Perpetual Preferred Stock to Streeterville in exchange for a $2,250,000 reduction in the outstanding balance of the August 2022 Royalty Interest.
• The total reduction in outstanding royalty interest obligations amounts to $6,500,000.
• The Series M Preferred Stock has a stated value of $25,000 per share and does not entitle holders to receive cash dividends.
• Holders of Series M Preferred Stock will accrue a Preferred Return at a rate of 10% per year for the first two years, 8% per year for years three and four, and 6% per year thereafter, payable quarterly via the issuance of additional Series M Preferred Stock.
• The Series M Preferred Stock votes together with Common Stock on an as-converted basis, subject to a 9.99% voting cap for any single holder.
• In a liquidation event, Series M Preferred Stock holders are entitled to receive the stated value plus any accrued but unpaid Preferred Return before any payments are made to common stockholders.
• The company has the right to exchange Series M Preferred Stock for Common Stock at its sole discretion, subject to certain conditions and a 9.99% beneficial ownership cap for holders.
• Extensive covenants are imposed on the company, requiring consent from a majority of Series M Preferred Stock holders for actions such as issuing equity securities with net proceeds exceeding $15,000,000 (excluding ATM/Exempt Issuances), increasing authorized shares, disposing of material assets, undertaking reverse stock splits (unless for Nasdaq deficiency), or consummating fundamental transactions.
• An Event of Default allows the Required Holders to force the company to redeem all outstanding Series M Preferred Stock for Common Stock at a price based on the stated value, accrued Preferred Return, and other amounts, using the greater of the Minimum Price or a Floor Price of $0.542 per share.

Sentiment

Score: 3

Explanation: While the company reduced royalty obligations, the terms of the new Series M Preferred Stock are highly restrictive and potentially dilutive, indicating financial distress and significant concessions to preferred holders. The extensive covenants severely limit future strategic and financial flexibility.

Positives

• Reduced outstanding royalty interest obligations by a total of $6.5 million, which can improve the company's balance sheet by converting debt-like obligations into equity.
• Avoids immediate cash outflows for royalty payments by settling obligations with preferred stock.

Negatives

• The issuance of Series M Preferred Stock introduces a new class of senior equity with significant rights and preferences, potentially complicating future capital structure management.
• The Series M Preferred Stock accrues a high Preferred Return (initially 10% per year) payable in additional preferred stock, leading to potential future dilution for common shareholders.
• The company is now subject to extensive covenants that severely restrict its operational and financial flexibility, requiring consent from preferred stockholders for key strategic and financial decisions.
• The forced redemption mechanism upon an Event of Default could lead to substantial dilution for existing common shareholders if the common stock price is low, as redemption is in common stock at a floor price of $0.542 per share.
• There is no established trading market for the Series M Preferred Stock, which limits liquidity for the holders of these shares.

Risks

• Dilution Risk: The Preferred Return is payable in additional Series M Preferred Stock, and the company's exchange right or forced redemption upon default can result in the issuance of common stock, potentially diluting existing common shareholders.
• Operational Restrictions: Extensive covenants limit the company's financial and strategic flexibility, requiring consent from preferred stockholders for key decisions, which could hinder growth or necessary restructuring.
• Liquidity Risk for Preferred Stock: No established trading market for Series M Preferred Stock means limited liquidity for holders.
• Default Risk: Failure to comply with covenants or pay amounts due can trigger an Event of Default, leading to forced redemption of preferred stock into common stock at potentially unfavorable terms for the company.
• Nasdaq Listing Compliance: The Exchange Cap and Stockholder Approval requirements relate to Nasdaq listing rules, indicating potential compliance challenges if large issuances are needed.
• Bankruptcy Impact: In a Chapter 7 bankruptcy, Series M Preferred Stock holders receive the same amount as common stockholders as if fully converted, potentially at a floor price of $0.542, which could still be preferential depending on the common stock price.

Future Outlook

The company's future financial and strategic flexibility will be significantly influenced by the terms of the Series M Preferred Stock, particularly the extensive covenants requiring holder consent for various corporate actions and potential future dilution from preferred return accrual and forced redemptions. The ability to raise additional capital or undertake strategic transactions is now subject to the approval of the Series M Preferred Stock holders.

Management Comments

• "Company acknowledges and understands that the representations and agreements of Company in this Section 5 are a material inducement to Investors decision to consummate the transactions contemplated herein."
• Lisa A. Conte and Carol R. Lizak certified the filing of the Certificate of Designation.

Industry Context

This transaction reflects a common strategy for companies, particularly in the biotech or early-stage sectors, to manage debt obligations by converting them into equity or equity-like instruments, especially when cash flow is constrained. Royalty interests are a form of financing often used by such companies. The extensive covenants suggest a high degree of control granted to the preferred stockholders, which can be typical for distressed or highly leveraged companies seeking to restructure.

Corporate Governance

Stakeholder Impact

• Shareholders (Common Stock): Potential for significant future dilution due to Preferred Return accrual in kind and forced redemption mechanisms. Reduced management flexibility due to extensive covenants may impact strategic growth opportunities.
• Preferred Stockholders (Series M): Gain significant control and protective provisions, including a preferential liquidation right and a guaranteed Preferred Return. However, liquidity is limited as there is no established trading market for the Series M Preferred Stock.
• Creditors: The reduction of royalty interest obligations could be seen as a positive step in debt management, but the new preferred stock's senior liquidation preference could impact other creditors in a dissolution scenario.

Next Steps

• Jaguar Health will continue to comply with the extensive covenants outlined in the Certificate of Designation for the Series M Preferred Stock.
• The company may exercise its right to exchange Series M Preferred Stock for Common Stock in the future, subject to the specified conditions.
• Holders of Series M Preferred Stock will receive Preferred Return payments quarterly in additional Series M Preferred Stock.

Key Dates

Recommendation

Keywords

Jaguar Health, SEC filing, 8-K, Series M Preferred Stock, royalty interest, debt reduction, equity issuance, corporate governance, preferred stock, Iliad Research and Trading, Streeterville Capital, financial restructuring, dilution, covenants, Nasdaq